Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CAPITAL ONE FINANCIAL CORPCOF · Entity 547 | Director | July 31, 2009 | August 03, 2009 |
| PALISADE BIO, INC.CUR · Entity 5803 | Director | July 02, 2018 | July 05, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CAPITAL ONE FINANCIAL CORP
Report date July 31, 2009 · Filed August 03, 2009
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 105,343 |
Reported balance
After 2009-07-31 transaction · row 1
1 source rowRow 1 · 2009-07-31 · Sale · Disposed 50,000 · Balance 105,343 F1: These shares were sold at prices ranging from $30.61to $30.87. Information regarding the number of shares sold at each separate price will be provided upon request. |
| Common StockSEC Table I · non-derivative | IndirectBy GRAT | 300,000 |
Reported balance
Holding disclosure · report date 2009-07-31 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 300,000 |
| Common StockSEC Table I · non-derivative | IndirectBy Helene Westreich Trust | 156,000 |
Reported balance
Holding disclosure · report date 2009-07-31 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 156,000 |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 67,590 |
Reported balance
Holding disclosure · report date 2009-07-31 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 67,590 |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were sold at prices ranging from $30.61to $30.87. Information regarding the number of shares sold at each separate price will be provided upon request.
PALISADE BIO, INC.
Report date July 02, 2018 · Filed July 05, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock Purchase OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.11 · Expires 2028-07-02 | Direct | 59,660 |
Reported balance
After 2018-07-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-07-02 · Grant · Acquired 59,660 · Balance 59,660 F1: Represents 50% of compensatory Annual Grant for director services of $100,000. The options vest quarterly on 9/30/18, 12/31/18, 3/31/19, and 6/30/19. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 50% of compensatory Annual Grant for director services of $100,000. The options vest quarterly on 9/30/18, 12/31/18, 3/31/19, and 6/30/19.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 06, 2003 Filed Jun 16, 2003 20:43 UTC | CAPITAL ONE FINANCIAL CORP COF · Entity 547 | GiftCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001242043-03-000002 · wes149.xml · nonDerivative · entry 1 WESTREICH STANLEY · CIK 0001238046 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 628,859 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.